The success of any company is through its management and leadership. MDI has a team of dedicated and experienced management specialists who seek new business opportunities and operate an efficient and profitable company. The company is overseen by its Board of Directors who offer an extensive knowledge base across business, finance and the health industry, who together, make the necessary decisions for the welfare of MDI’s shareholders and the growth of the company.
Brent MacGregor (from 1 November 2020)
Chief Executive Officer
Chief Financial Officer and Company Secretary
Chief of Operations and Supply Chain
Chief Scientific Officer
Head of Quality
Head of Medical Affairs
Chi Wai Ng
Head of Regulatory Affairs
Head of Production
Sales & Marketing
Board of Directors
Mr. David Williams, B.Ec (Hons), M.Ec, FAICD
David is Managing Director of Kidder Williams Ltd, with over 30 years experience in the investment banking sector. He is also Chairman of PolyNovo Ltd and RMA Global Limited.
Mr. Max Johnston
Max was appointed a Director of the company with effect from November 2012. Max is also non-executive director of PolyNovo Limited, Bard1 Sciences Limited and is also a Non-executive Director and Chairman of Auscann Group Holdings Limited.
For 11 years he was President and Chief Executive Officer of Johnson & Johnson Pacific and an Executive Director of Johnson & Johnson.
Max has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of ASMI. Max has had extensive overseas experience during his career in leading businesses in both Western and Central-Eastern Europe, Africa as well as Asia-Pacific.
Mr Hoare is the Managing Director of Lohmann & Rauscher (Australia and New Zealand), a private EU based medical device company. Previously, he was Managing Director of Smith & Nephew (Aus/NZ). which is one of the company’s largest global subsidiaries outside of the USA. Until 2014 he served as President of Smith & Nephew’s Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in Marketing, Divisional and General Management. Mr Hoare’s career also included a senior role at Bristol-Myers Squibb in surgical products, and Vice-Chair of Australia’s peak medical device body, Medical Technology Association of Australia. Leon is also a Non-executive Director of PolyNovo Limited (ASX: PNV).
Leon’s 30 years of healthcare industry experience, spanning multiple medical technologies, and management of all aspects of a major market-leading medical device company, coupled with extensive experience in Asia, will add depth to the Board of Directors.
Philip, a Chartered Accountant, has an extensive finance background and commenced working in investment banking in 1996 at Hambros Corporate Finance following ten years industry experience in senior finance roles with ASX listed public company OAMPS Limited. Prior to these roles, Philip worked for ten years within the Assurance Division at Arthur Andersen & Co.
From January 2006 to July 2013 Philip was an Executive Director at Corporate Finance Advisory firm Kidder Williams. Philip is also a Director of PolyNovo Limited (ASX:PNV) and RMA Global Limited (ASX:RMY).
Philip is also Chairman of the MDI Audit and Risk Committee.
Christine has a Bachelor of Science and major in Economics (Hons: Chem) from Monash University, Certificate in Intellectual Property Law from Queen Mary College, University of London, Masters of Enterprise from Melbourne University and is a member of the Chartered Institute of Patent Attorneys UK. Christine has also been on the Board of the Institute of Patent and Trade Mark Attorneys of Australia since 2010.
Christine is an experienced patent and trademark attorney, and a business development professional having more than 30 years’ experience locally and internationally. Christine is also a Non-executive Director of PolyNovo Limited (ASX: PNV).
Gordon has enjoyed a long and successful international business career. For over 30 years he was a key part of the internationalisation of the CSL Group, a global specialty biotechnology company that was established in Australia and grew to become Australia’s largest public company. Gordon held a range of business and functional leadership roles within CSL including Chief Financial Officer. At the time of his retirement from CSL, he was the President of Seqirus where he led the 3-year turnaround of that business into one of the most successful vaccine companies in the world. In 2016 Seqirus was highly unprofitable with a turnover of circa $700m. By 2019 the business generated circa $150m EBIT from a turnover of $1.2b.
Gordon holds a Bachelor of Engineering (Honours), a Graduate Diploma in Computer Science and an MBA as well as being a CPA and a graduate of the Australian Institute of Company Directors.